Page 15 - Sun Pharma
Pharma shares under pressure;Glenmark hits 52-week low, Sun Pharma falls 6%
Marksans Pharma, Ajanta Pharma, Morepen Lab, Alkem Laboratories, SPARC and Aarti Drugs were down in the range 3% to 4% on the BSE.
 "Pharma shares under pressure;Glenmark hits 52-week low, Sun Pharma falls 6%")
Sun Pharma: Generic, speciality drugs can drive medium-term earnings growth
Given pricing pressure in the US on its generic portfolio, Sun Pharma has been focusing on bringing to the market its next growth vehicle in the form of speciality drugs
 "Sun Pharma: Generic, speciality drugs can drive medium-term earnings growth")
Sun Pharma gains on USFDA nod for psoriasis drug Ilumya
The stock was trading 2% higher at Rs 515 as compared to a marginal 0.05% gain in the S&P BSE Sensex at 09:17 am.
 "Sun Pharma gains on USFDA nod for psoriasis drug Ilumya")
Sun Pharma gets approval for psoriasis drug Ilumya, its first biologic drug
The market for psoriasis drugs in US is over $ 6 billion and the approval allows the drugmaker to expand its portfolio in dermatology space
 "Sun Pharma gets approval for psoriasis drug Ilumya, its first biologic drug")
Learning from auto sector on reducing attrition rates: Sun Pharma MD
Dilip Shanghvi cited the example of auto components manufacturer Motherson Sumi, which has only 2% attrition rate
 "Learning from auto sector on reducing attrition rates: Sun Pharma MD")
Sun Pharma Halol facility gets three observations by US FDA
Down from 9 it received in December 2016
 "Sun Pharma Halol facility gets three observations by US FDA")
Sun Pharma turns volatile after three observations for Halol facility
The stock was up 3.5% at Rs 561 on the BSE at 02:34 pm, after the company said the USFDA issued Form 483, with three observations, for its Halol facility in Gujarat.
Sun Pharma recalls over 17,500 bottles of nasal spray solution from US
The bottles are being recalled following a failure to meet the % RSD requirement in the test for Droplet Size during the 6 month long term stability test station
Sun Pharma eclipsed by 75% fall in Q3 net profit on weak US business
The results were below Bloomberg's revenue and profit estimate by over 5 per cent and 61 per cent, respectively
 "Sun Pharma eclipsed by 75% fall in Q3 net profit on weak US business")
Sun Pharma Q3 net profit plunges 75% to Rs 3.6 bn on weak US sales
Total revenue from operations fell 16 percent to Rs 66.53 billion
Pharma shares gain; Sun Pharma hits seven-month high
Wockhadrt, Biocon, Ipca Laboratories, Glenmark Pharmaceuticals, Lupin and Cadila Healthcare were up more than 2% on the National Stock Exchange.
Sun Pharma's specialty business gets USFDA boost
Stock gained over 6% as FDA accepts application for new ophthalmic drug
Specialty drug boost for Sun Pharma
Valuations, however, already factor in some of the positives
Sun Pharma shares rise over 6% after USFDA accepts new drug application
The stock closed at 6.12 per cent to Rs 573.50 on BSE
 "Sun Pharma shares rise over 6% after USFDA accepts new drug application")
USFDA accepts Sun Pharma's new eye drug application
Shares of Sun Pharma were up 5.75 per cent at Rs 571.55 on the BSE
 "USFDA accepts Sun Pharma's new eye drug application")
Sun Pharma up 4% on USFDA acceptance of new drug application
The stock was up 4% at Rs 564 on the BSE with trading volumes on the counter more than doubled.
Sun Pharma recalls two batches of diabetic drug from US market
Riomet is an oral diabetes medicine that helps control blood sugar level
Sun Pharma's specialty drugs face competition in US
The Mumbai-based pharma major reported 59% decline in its net profit for the quarter ending September to Rs 912 cr
No major respite for Sun Pharma
The Sun Pharmaceutical stock, after seeing some gains post September quarter results, is now marginally below pre-result levels despite the recent positive news flow. So, what's keeping sentiment low in the counter?First the positive part. The latest development pertains to the restart of supplies of some products to the US by Sun from its key plant in Halol (Gujarat). A Credit Suisse report, referring to IMS data, also indicates that Sun's oncology generics of Gleevac has gained market share sequentially in the December quarter (Q3) so far, on a trailing basis. The Gleevac generics, which has seen competitive pressures post Sun's exclusivity ended in FY17 and contributed $230 million to Sun's FY17 sales, was estimated to see its contribution drop by a third in FY18. So, the news of it gaining market share (19 per cent sequential revenue growth) is positive. This, coupled with Sun's re-entry into key segments such as neurology (Duloxetine, Carbidopa and Levodopa) and ENT (Azelastine ..
Sun Pharma recalls diabetes drug in US over microbial contamination
Use of contaminated Riomet potentially could result in a risk of infection, especially in the immunocompromised patient.
 "Sun Pharma recalls diabetes drug in US over microbial contamination")
